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INTRODUCTION
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide, and it commonly occurs in patients at high risk for this disease, especially those with liver cirrhosis (1) . The risk of hepatocarcinogenesis depends on background liver factors, of which fibrosis is a major determinant (2, 3) . An important question is whether hepatocarcinogenesis will accelerate as liver fibrosis progresses. Indeed, a related study reported that a hepatic venous pressure gradient greater than 15 mm Hg is a positive predictor for the development of HCC in patients with decompensated alcoholic cirrhosis (4) . However, it is not definite whether the same relationship is still valid for patients with compensated liver cirrhosis. It is also not definite whether the risk of development of new HCC nodules will increase in HCC patients with portal hypertension who have already received local curative treatments, compared to those without portal hypertension.
Although portal hypertension is conventionally evaluated by measuring the hepatic venous pressure gradient (HVPG) following percutaneous catheterization, non-invasive imaging is also widely used in clinical practice (5, 6) . In fact, non-invasive diagnosis of clinically relevant portal hypertension (CRPH) is considered useful in the determination of treatment strategies Purpose: To evaluate the effect of portal hypertension on the tumor recurrence in patients with hepatocellular carcinoma (HCC) and without hepatic decompression following radiofrequency ablation (RFA). Materials and Methods: Treatment-naïve HCC patients within the Milan criteria and with Child-Pugh class A were included in this study, who had performed RFA in our hospital between January 2010 and March 2017. Univariate and multivariate analyses using the Cox proportional hazard model were performed to find the predictors of local or distant tumor recurrence. Results: Overall, 178 patients were included in this study. Median follow-up period was 40.2 months. The difference in the local tumor progression rates depending on the absence or presence of portal hypertension was not statistically significant (p = 0.195). The 1-, 3-, and 5-year distant intrahepatic tumor spread rates were 6.6%, 29.5%, and 537% in patients without portal hypertension, and 23.4%, 51.9%, and 63.6% in patients with portal hypertension, respectively. The difference was statistically significant (p = 0.011). Univariate and multivariate analysis showed that portal hypertension was an independent predictor for distant intrahepatic tumor spread (p = 0.008). for patients with HCC (6) (7) (8) . In this study, we evaluated whether the existence of CRPH, which was non-invasively diagnosed, could affect tumor recurrence in HCC patients without hepatic decompensation who underwent radiofrequency ablation (RFA) (9-13).
MaTeRIalS aND MeThODS

Patient Selection
Informed consent was obtained from all the patients after the Procedures were performed with a 3.5-MHz convex-array transducer by using a free-hand technique. Percutaneous RFA was mostly performed with real-time sonographic guidance.
When sonographic guidance was not technically feasible, CT or fluoroscopy guidance was used. The ablation procedure was terminated when the size of the ablation zone was observed to be large enough to achieve at least 5 mm of safety margin around the index tumors (9) . All ablation procedures were performed by a radiologist with 11 years of experience in ablation procedures at the start of this study (Y.K.C). Vital signs were monitored during the entire procedure. was larger than 12 cm on the axial images, or larger than 13 cm on the coronal images, we considered severe splenomegaly to be present (14) . Thrombocytopenia was defined when the platelet count was below 100000/mm 3 (15) . that were previously considered to be completely ablated (25) .
CT and MRI Imaging Interpretation
If local tumor progression was judged to be present, additional RFA or surgical resection was performed when appropriate (26) . Transarterial chemoembolization (TACE) or radiation therapy was considered when RFA or surgical resection were neither effective nor feasible.
Statistical Analysis
To investigate the effect of portal hypertension on tumor progression, univariate and multivariate analyses were performed by using the Cox proportional hazard model. Prognostic factors included in the analysis were age, sex, hepatitis C infection, heavy alcoholics, Child-Pugh score, multinodularity of HCC, presence of HCC nodules > 3 cm, tumor location, operative RFA, and portal hypertension. Parameters that proved to be significant or marginally significant in the univariate analysis (p < 0.1) were subsequently evaluated using multivariate analysis.
ReSUlTS
Patient Selection
Overall, 178 patients were included in this study. The maximal tumor diameters were 2.0 ± 0.8 cm, mean age was 66.7 ± 5.0 years (ranging from 47 to 87 years old), and median followup period was 42.8 months. The follow-up was terminated on June 18th, 2018. All except one patient were followed-up longer than one year, and the early sensor rate within two years was 17.1%. The two groups were similar in terms of baseline characteristics except the presence of portal hypertension and the ChildPugh score (Table 1) .
Tumor Progression Rates
After RFA, primary and secondary efficacy in local tumor (Fig. 1A) . The difference was not statistically significant (p = 0.195). (Fig. 1B) . The development and progression of liver fibrosis are known to be associated with hepatocyte death and a subsequent inflammatory response, both of which involve reactive oxygen species accumulation in injured hepatocytes (27) . Considering that the risk of human HCC recurrence after hepatectomy seems to be correlated with protein oxidation in the liver, increased oxidative stress in liver parenchymal cells may explain the close relationship between liver fibrosis and hepatocarcinogenesis (3).
It is well known that liver fibrosis can act as an adverse prognostic factor for survival because of hepatic decompensation as well as the development of HCC (4). Therefore, reversal of liver fibrosis before the development of portal hypertension, if possible, will be clinically important in reducing the development of HCC as well as hepatic decompensation (28, 29 It seems that the potential for the development of HCC or intrahepatic metastasis increases as liver fibrosis progresses, even for patients without hepatic decompression. For the other prognostic factor (recurrence-free survival) which was identified in this study using multivariate analysis, it could be inferred that multinodularity was also an independent significant factor for tumor progression (1, 30) .
This study has several limitations. First of all, non-invasive imaging tools were used to determine portal hypertension (31) .
Although portal hypertension is conventionally evaluated by measuring the HVPG, non-invasive imaging tools are also widely used in clinical practice (5, 6) . Secondly, the significance of the results may be limited because of its retrospective nature. A future prospective multi-center study may reinforce the significance of this study. Finally, this study was conducted for patients who were already diagnosed with HCC. Therefore, the results of this study may not be applicable to high risk patients who have not been diagnosed with HCC yet.
In conclusion, even among the HCC patients without hepatic decompensation, a higher distant intrahepatic tumor progres- 
